Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Execs On The Move, March 2014

This article was originally published in Start Up

Executive Summary

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

You may also be interested in...



Executives On The Move: Boehringer Announces US Promotion, Immatics Chooses A CMO And DalCor Pharma Fills C-Suite Commercial Post

Boehringer Ingelheim announces its BI Pharma president to take helm from retiring US country managing director and chief executive officer. Immunotherapeutics developer Immatics Biotechnologies chooses GSK cell therapy head as CMO, and precision medicine firm DalCor Pharmaceuticals picks a chief commercial officer.

Executives On The Move: Clinical Positions Filled At Gilead, Sanifit and Spectrum, And Ferring Pharma US Officer Is Promoted

Anti-viral pharma Gilead Sciences, vascular calcification treatment firm Sanifit and hematology and oncology drug developer Spectrum Pharmaceuticals each select a new VP, clinical development. Also, to oversee its group in the US, multinational Ferring Pharmaceuticals promotes its US chief commercial officer to president.

Executives On The Move: Ipsen Decides On New Leader, A CSO for 4P-Pharma And A CFO During Transition for Histogen

Paris, France-based Ipsen decides on a Sanofi Pasteur exec for CEO and Roche Institute head joins cancer and inflammatory therapy company 4P-Pharma as CSO. Meanwhile, regenerative medicine firm Histogen brings on a new CFO during its transition to a public company.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel